Please assess the completion status of the following clinical trial:

Trial Title: SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 20 years of age or greater at the time of informed consent~* Part 1: Patients with histologically or cytologically confirmed advanced solid tumors refractory to standard therapies or without standard therapies.~* Part 2: patients with advanced solid tumors\* refractory to standard therapies or without standard therapies.~  * \*metastatic breast cancer, small cell lung cancer and other tumors decided based on the Part 1 results~* ECOG performance status 0-1~* Patients with adequate bone marrow, liver, renal, cardiac and pulmonary function as assessed by the following:~  * Absolute neutrophil count (ANC) ≥ 1500/μL, who has not received supportive care of treatment with GCS within 2 weeks before the entry~ * Platelet count ≥ 100,000/μL and Hemoglobin ≥ 9g/dL in patients received no blood transfusions within 2 weeks before the study entry~ * Serum creatinine ≤ 1.5 x upper limit normal (ULN) or estimated creatinine clearance ≥ 50 mL/min using Cockcroft-Gault equation~ * Serum total bilirubin ≤ 1.5 x ULN in patients not suffering from Gilbert's syndrome~ * ALT and AST ≤ 3.0 x ULN (≤ 5.0 x ULN if liver lesions)~ * 12-lead ECG normal~ * LVEF ≥ 55% by echocardiography~ * SpO2 ≥ 95% or PaO2 ≥ 65mmHg~* Acute toxicity in prior treatment has recovered to baseline or CTCAE Grade 0-1 except the adverse events that, in the judgment of the investigator or sub-investigator, would not provide safety risks in the study.~* Serum/urine pregnancy tests performed before the study entry are negative.~* Male and female patients of childbearing potential should give their consent to use adequate contraceptive measures during the study and 180 days after completing study treatment.~* Provision of written, signed and dated informed consent by the patient or legally acceptable representative after the receipt of adequate information regarding the study~* Ability to understand participation in the study, visiting/treatment plan, sampling/analyses and other study procedures; and willingness to follow them~Exclusion Criteria:~* Active, uncontrollable or symptomatic metastatic tumors in CNS~* Complications of interstitial lung disease, pulmonary fibrosis and emphysema diagnosed by chest-X ray or CT scan~* Medical history of radiation, idiopathic or drug-induced pneumonitis~* Major surgery within 4 weeks before study entry or planning it within 4 weeks~* Treatment with immunotherapy, therapeutic antibody or biologics within 4 weeks or their 5 half-lives before study entry, whichever is longer~* Treatment with cytocidal chemotherapy or hormonal therapy within 14 days~* Radiotherapy within 4 weeks before study entry~* Palliative radiotherapy to control metastatic bone pain within 7 days before study entry~* Malabsorption syndrome or full/partial gastric resection~* Patients intolerable to oral administration in the judgment of the investigator or sub-investigator~* Patients under following medical treatment~  * Anticancer therapy approved for advanced cancers~ * Study treatment in other clinical trials~* Active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV) detected in blood test~* Lactating women~* Medical history of allergy to the agents similar to the investigational drug such as alkylating agents or purine nucleoside derivatives~* Medical history of allergy to Polyoxyl 40 hydrogenated castor oil or gelatin capsule~* Severe acute or chronic physical/mental condition or laboratory abnormalities which could interfere with evaluation of study treatment or results, or which is likely to progress/worsen due to the participation in the study or administration of SyB C-0501~* Any condition that, in the opinion of the investigator or sub-investigator, makes the patient inappropriate for the study participation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SyB C-0501 (Type: EXPERIMENTAL): SyB C-0501 (Oral Bendamustine) will be administered orally once a day (specified dose). The treatment period of 21 days (Cohort 1; 7 days of administration + 14 days of observation or Cohort 2; 14 days of administration + 7 days of observation or Cohort 3; 21 days of administration) constitutes 1 cycle.~Part 1: dose escalation to determine MTD, RD and dosing schedule Part 2: dose expansion at RD

Based on this trial design, predict the completion outcome and termination type (if applicable).